Pay in 4 interest-free payments of $5.83 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
This question has gained traction online as interest in glucagon-like peptide-1 (GLP-1) receptor agonists for diabetes and weight management has surged
Brand-name GLP1 + GIP may be covered under some Medicare Part D or Medicare Advantage plans when prescribed for type 2 diabetes, depending on your plans formulary
Check out the episode below, then read on to learn all about the difference between Semaglutide and Tirzepatide
Releasing Q2 earnings on Monday, Hims & Hers Co-Founder and CEO Andrew Dudem said users of its personalized GLP-1 treatment plans had lost an average 10.3% of their body weight over six months, and that only 25% of them had discontinued treatment, particularly encouraging when considering discontinuation rates in certain publicly available studies reached approximately 80% percent by six months. Saying that personalized treatments allow patients to receive clear treatment instructions and educational content while also accessing tools such as water intake trackers and calorie counters, Dudem complained of pushback from traditional incumbents. During its own earnings call on Wednesday, Novo Nordisk doubled down against GLP-1 compounders that it says are still around despite the end of an FDA-granted grace period in May
US$ 20.10
US$ 22.38
US$ 21.98
US$ 21.11
